Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals names Renee Gala CEO; Bruce Cozadd to retire as CEO

Neutral Impact 4 of 5 leadership Written later

Jazz Pharmaceuticals said its board appointed President and Chief Operating Officer Renee Gala as President and Chief Executive Officer, effective August 11, 2025, and she will join the board as a director on that date. Co-founder Bruce Cozadd will serve as CEO until August 11, 2025, then in a transition role through September 12, 2025, before retiring and remaining Chairperson of the Board.

Key points

  • Gala becomes CEO and a director effective August 11, 2025; the board increases from 12 to 13 members.
  • Gala's annual base salary rises to $1,200,000 from $900,000, and her target bonus to 110% of base salary from 80%.
  • A one-time promotion equity grant with an approximate grant date value of $6,500,000 is included, on top of her previous 2025 annual grant of approximately $6,000,000.
  • Cozadd remains in a transition role through September 12, 2025, then retires and continues as Chairperson.

The filing

CompanyJazz Pharmaceuticals (JAZZ)
Form8-K, current report
Filed with the SECJul 10, 2025, 7:53 AM ET
Accession number0001193125-25-157388

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 10, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.